07/07/15

Smart antibodies offer hope for HIV vaccine

clinical trials
Copyright: Flickr/Army Medicine

Send to a friend

The details you provide on this page will not be used to send unsolicited email, and will not be sold to a 3rd party. See privacy policy.


If you are unable to listen to this audio, please update your browser or click here to download the file [7.3MB].

Similar to the influenza virus, HIV mutates constantly. But while developing fresh vaccines every year can target influenza, HIV is much harder to fight. One person infected with the virus carries hundreds of thousands of its variations, preventing the use of traditional vaccines that target a single version of a virus.

Starting from the so-called naive antibodies found in humans, scientists at The Scripps Research Institute in the United States are breeding a new class of smart antibodies, called broadly neutralising antibodies, that could protect against the whole spectrum of HIV mutations.
 
In this audio interview, lead researcher Dennis Burton says the method raises hopes for the development of a HIV vaccine.